文献速递血脂与心血管预防冠心病

REDUCE-IT肾脏分析:不同肾功能人群中二十碳五烯酸乙酯的获益

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.
PubMed 文献 · Circulation · 2021-10-28

REDUCE-IT肾脏分析纳入8179例已确诊心血管疾病或糖尿病且接受他汀治疗、甘油三酯升高的患者,按基线eGFR分层。结果显示二十碳五烯酸乙酯(4 g/日)在各eGFR类别中均一致降低主要和关键次要复合终点,eGFR<60 mL·min⁻¹·1.73 m⁻²患者绝对获益最大且相对风险降低相似,未观察到eGFR显著变化。

要点

  • 二十碳五烯酸乙酯在各基线eGFR类别中一致降低缺血事件复合终点。
  • eGFR<60患者主要复合终点绝对风险降低最大(21.8% vs 28.9%)。
  • eGFR<60患者心血管死亡数值下降最明显(7.6% vs 10.6%)。

核心结论

  • 在REDUCE-IT中,二十碳五烯酸乙酯在广泛基线eGFR范围内减少致死性和非致死性缺血事件。

研究设计与样本

  • REDUCE-IT为多中心、双盲、安慰剂对照试验,随机分配接受他汀治疗、甘油三酯135-499 mg/dL、有心血管疾病或糖尿病且合并1项额外危险因素的患者至二十碳五烯酸乙酯4 g/日或安慰剂。
  • 本次分析纳入8179例REDUCE-IT患者,按预设eGFR类别分组,分析二十碳五烯酸乙酯对主要终点和关键次要终点的影响。

主要发现

  • 中位基线eGFR为75 mL·min⁻¹·1.73 m⁻²(范围17-123 mL·min⁻¹·1.73 m⁻²)。
  • 各研究访视中,二十碳五烯酸乙酯组与安慰剂组的中位eGFR无有意义变化。
  • eGFR<60 mL·min⁻¹·1.73 m⁻²患者中,二十碳五烯酸乙酯组主要复合终点发生率为21.8%,安慰剂组为28.9%(HR 0.71,95%CI 0.59-0.85;P=0.0002)。
  • eGFR<60 mL·min⁻¹·1.73 m⁻²患者中,关键次要复合终点发生率为16.8% vs 22.5%(HR 0.71,95%CI 0.57-0.88;P=0.001)。
  • eGFR<60 mL·min⁻¹·1.73 m⁻²组心血管死亡数值下降最大(7.6% vs 10.6%;HR 0.70,95%CI 0.51-0.95;P=0.02)。

关键数值与推荐

  • 主要终点为心血管死亡、非致死性心肌梗死、非致死性卒中、冠状动脉血运重建或不稳定心绞痛的复合终点。
  • 关键次要终点为心血管死亡、非致死性心肌梗死或非致死性卒中的复合终点。
  • eGFR<60 mL·min⁻¹·1.73 m⁻²患者中,二十碳五烯酸乙酯组房颤/房扑发生率为4.2%,安慰剂组为3.0%(HR 1.42,95%CI 0.86-2.32;P=0.17)。
  • eGFR<60 mL·min⁻¹·1.73 m⁻²患者中,严重出血发生率为5.4% vs 3.6%(HR 1.40,95%CI 0.90-2.18;P=0.13)。
  • 房颤/房扑和严重出血的HR在各eGFR类别间相似(交互作用P分别为0.92和0.76)。

临床怎么用

  • 对于已确诊心血管疾病或糖尿病、接受他汀治疗且甘油三酯升高的患者,二十碳五烯酸乙酯4 g/日可在广泛eGFR范围内一致降低缺血事件风险。
  • eGFR<60 mL·min⁻¹·1.73 m⁻²患者使用二十碳五烯酸乙酯的绝对获益最大,但需关注房颤/房扑和严重出血的数值升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic kidney disease is associated with adverse outcomes among patients with established cardiovascular disease (CVD) or diabetes. Commonly used medications to treat CVD are less effective among patients with reduced kidney function. METHODS: REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) was a multicenter, double-blind, placebo-controlled trial that randomly assigned statin-treated patients with elevated triglycerides (135-499 mg/dL) who had CVD or diabetes and 1 additional risk factor to treatment with icosapent ethyl (4 g daily) or placebo. Patients from REDUCE-IT were categorized by prespecified estimated glomerular filtration rate (eGFR) categories to analyze the effect of icosapent ethyl on the primary end point (composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina) and key secondary end point (a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke). RESULTS: Among the 8179 REDUCE-IT patients, median baseline eGFR was 75 mL·min-1·1.73 m-2 (range, 17-123 mL·min-1·1.73 m-2). There were no meaningful changes in median eGFR for icosapent ethyl versus placebo across study visits. Treatment with icosapent ethyl led to consistent reduction in both the primary and key secondary composite end points across baseline eGFR categories. Patients with eGFR <60 mL·min-1·1.73 m-2 treated with icosapent ethyl had the largest absolute and similar relative risk reduction for the primary composite end point (icosapent ethyl versus placebo, 21.8% versus 28.9%; hazard ratio [HR], 0.71 [95% CI, 0.59-0.85]; P=0.0002) and key secondary composite end point (16.8% versus 22.5%; HR 0.71 [95% CI, 0.57-0.88]; P=0.001). The numeric reduction in cardiovascular death was greatest in the eGFR <60 mL·min-1·1.73 m-2 group (icosapent ethyl: 7.6%; placebo: 10.6%; HR, 0.70 [95% CI, 0.51-0.95]; P=0.02). Although patients with eGFR <60 mL·min-1·1.73 m-2 treated with icosapent ethyl had the highest numeric rates of atrial fibrillation/flutter (icosapent ethyl: 4.2%; placebo 3.0%; HR 1.42 [95% CI, 0.86-2.32]; P=0.17) and serious bleeding (icosapent ethyl: 5.4%; placebo 3.6%; HR, 1.40 [95% CI, 0.90-2.18]; P=0.13), HRs for atrial fibrillation/flutter and serious bleeding were similar across eGFR categories (P-interaction for atrial fibrillation/flutter=0.92; P-interaction for serious bleeding=0.76). CONCLUSIONS: In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01492361.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Majithia A, Bhatt DL, Friedman AN, et al. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. Circulation. 2021. PMID: 34706555. doi:10.1161/CIRCULATIONAHA.121.055560

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。